Valeur pronostique des sous-ensembles de lymphocytes du sang périphérique chez les patients atteints de cancer solide: une étude rétrospectiveIntroduction. Des sous-ensembles de lymphocytes sont importants dans la régulation de l'immunité et la destruction spécifique des cellules tumorales et semblent être fortement associés au développement de tumeurs solides. Cependant, leur pertinence pronostique chez les patients cancéreux reste incertaine. Le but de l'étude était de déterminer si un sous-ensemble de lymphocytes dans le sang périphérique pouvait constituer des marqueurs pronostiques pour les patients atteints de cancers solides. Matériel et méthodes. Une recherche dans la base de données de 2010 à 2020 a été menée pour identifier les publications qui explorent l'association de différents sous-ensembles de lymphocytes avec la survie globale et la survie sans maladie chez les patients atteints de cancer. Résultats. Vingt-neuf articles portant sur 14 tumeurs malignes différentes ont été inclus: 21 paramètres immunitaires évalués avant la chirurgie et 8 après la

Chemotherapy, the most widely used therapy in oncology, leads to the accumulation of reactive oxygen species, which often generates adverse effects in patients. To reduce the oxidative stress due to either the action of cytostatics or pathological tumour mechanisms, we analyzed the effectiveness of antioxidants. The use of antioxidants as adjuvant therapy can improve the therapeutic effects by potentiating the antitumour action of cytostatics and reducing their toxicity to healthy tissues.The aim of this study was to evaluate the efficacy of resveratrol administered 3 days after Epirubicin in Wistar rats inoculated with Walker tumour 256. In our experiment we evaluated three indices of oxidative stress and found that the lowest values were recorded at the group receiving resveratrol, thus emphasizing the beneficial antioxidant action of resveratrol.

Objective. To emphasize diagnostic and therapeutical difficulties of tumoral diseases of the temporal bone in children. They need early clinical and imagistic addressing and full histologic examination, some of these tumors benefiting a favorable prognosis with proper oncologic therapy. Material and method. 2 patients with Langerhans cell hystiocitosis are presented, stressing clinical key points that account for late diagnosis and treatment. Conclusions. Surgery can be useful for local control of the disease. Use of conservative methods seems appropriate, in conjunction with oncologic therapy.

the involvement of immune inhibitory cytokines and upregulation of are endogenous molecules that have the ability to form a signaling network modulating multiple targets simultaneously. Our group has recently reported the involvement of MALAT-1 in tuning the immunooncogenic profile of BC. Yet, microRNA-30a-5p is a novel miRNA in terms of immunoncology and its involvement in MALAT-1 modulatory network is yet to be explored. The aim of this study was to investigate the involvement of miR-30a-5p in MALAT-1circuit and its impact of PD-L1, MIF, IL-10 and TNF-a in BC.Methods: BC patients (n¼24) were recruited. Bioinformatics analysis was performed. MDA-MB-231 cells were cultured transfected by miR-30a-5p oligonucleotides and MALAT-1 siRNAs using Hiperfect Transfection protocol. RNA was extracted using biazol, reverse transcribed and quantified using q-RTPCR.Results: MALAT-1 and miR-30a-5p are paradoxically acting ncRNAs in BC patients. MALAT-1 is an upregulated oncogenic lncRNA while miR-30a-5p is a downregulated tumor suppressor miRNA in BC patients. In-silico analysis showed a strong binding of miR-30a-5p to MALAT-1. Experimentally, ectopic expression of miR-30a-5p represses MALAT-1 levels while MALAT-1 siRNAs induced miR-30a-5p levels in MDA-MB-231 cells. miR-30a-5p mimics and/or MALAT-1 siRNAs resulted in a marked repression of PD-L1, MIF, IL-10 and TNF-a.Conclusions: MALAT-1/miR-30a-5p are vital players releasing the immune surveillance brakes supported by BC cells. Dual targeting of MALAT-1 and miR-30a-5p is novel immune-oncological therapeutic approach in BC.Legal entity responsible for the study: German University in Cairo.

No abstract